A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome

Tumor lysis syndrome (TLS), including hyperuricemia, is a frequent serious complication in patients with hematologic malignancies. This study in Japanese patients evaluated the efficacy, safety, and pharmacokinetic profile of rasburicase in pediatric patients with hematologic malignancies. Patients...

Full description

Saved in:
Bibliographic Details
Published in:International journal of hematology 2009-11, Vol.90 (4), p.492-500
Main Authors: Kikuchi, Akira, Kigasawa, Hisato, Tsurusawa, Masahito, Kawa, Keisei, Kikuta, Atsushi, Tsuchida, Masahiro, Nagatoshi, Yoshihisa, Asami, Keiko, Horibe, Keizo, Makimoto, Atsushi, Tsukimoto, Ichiro
Format: Article
Language:English
Subjects:
Adolescent
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Child
Child, Preschool
Drug Hypersensitivity - complications
Female
Hematologic and hematopoietic diseases
Hematologic Neoplasms - complications
Hematologic Neoplasms - drug therapy
Hematology
Humans
Hyperuricemia - drug therapy
Hyperuricemia - etiology
Infant
Male
Medical sciences
Medicine
Medicine & Public Health
Metabolic diseases
Oncology
Original Article
Other metabolic disorders
Purines and pyrimidines (gout, hyperuricemia...)
Recombinant Proteins - adverse effects
Recombinant Proteins - blood
Recombinant Proteins - pharmacokinetics
Recombinant Proteins - therapeutic use
Risk Factors
Treatment Outcome
Tumor Lysis Syndrome - etiology
Urate Oxidase - adverse effects
Urate Oxidase - blood
Urate Oxidase - pharmacokinetics
Urate Oxidase - therapeutic use
Uric Acid - blood
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tumor lysis syndrome (TLS), including hyperuricemia, is a frequent serious complication in patients with hematologic malignancies. This study in Japanese patients evaluated the efficacy, safety, and pharmacokinetic profile of rasburicase in pediatric patients with hematologic malignancies. Patients aged
ISSN:0925-5710
1865-3774
DOI:10.1007/s12185-009-0402-6